Graft-versus-host disease classification: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) |
||
Line 7: | Line 7: | ||
==Classification== | ==Classification== | ||
Clinically, graft-versus-host-disease is divided into [[Acute (medical)|acute]] and [[chronic (medicine)|chronic]] forms. | |||
* The ''acute'' or ''fulminant'' form of the disease (aGVHD) is normally observed within the first 100 days post-transplant<ref>[http://www.marrow.org/PHYSICIAN/improved_management_gvhd.html Graft versus Host Disease], from the [[National Marrow Donor Program]]</ref>, and is a major challenge to transplants owing to associated morbidity and mortality<ref>{{cite journal |author=Goker H, Haznedaroglu IC, Chao NJ |title=Acute graft-vs-host disease: pathobiology and management |journal=Exp. Hematol. |volume=29 |issue=3 |pages=259–77 |year=2001 |pmid=11274753 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0301-472X(00)00677-9}}</ref>. | |||
* The ''chronic'' form of graft-versus-host-disease (cGVHD) normally occurs after 100 days. The appearance of moderate to severe cases of cGVHD adversely influences long-term survival <ref>{{cite journal |author=Lee SJ, Vogelsang G, Flowers ME |title=Chronic graft-versus-host disease |journal=Biol. Blood Marrow Transplant. |volume=9 |issue=4 |pages=215–33 |year=2003 |pmid=12720215 |doi=10.1053/bbmt.2003.50026 |url=}}</ref>. | |||
This distinction is not arbitrary: acute and chronic graft-versus-host-disease appear to involve different [[immune cell]] subsets, different [[cytokine]] profiles, somewhat different host targets, and respond differently to treatment. | |||
==References== | ==References== |
Revision as of 16:46, 3 June 2016
Graft-versus-host disease |
Differentiating Graft-versus-host disease from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Graft-versus-host disease classification On the Web |
American Roentgen Ray Society Images of Graft-versus-host disease classification |
Risk calculators and risk factors for Graft-versus-host disease classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Classification
Clinically, graft-versus-host-disease is divided into acute and chronic forms.
- The acute or fulminant form of the disease (aGVHD) is normally observed within the first 100 days post-transplant[1], and is a major challenge to transplants owing to associated morbidity and mortality[2].
- The chronic form of graft-versus-host-disease (cGVHD) normally occurs after 100 days. The appearance of moderate to severe cases of cGVHD adversely influences long-term survival [3].
This distinction is not arbitrary: acute and chronic graft-versus-host-disease appear to involve different immune cell subsets, different cytokine profiles, somewhat different host targets, and respond differently to treatment.
References
- ↑ Graft versus Host Disease, from the National Marrow Donor Program
- ↑ Goker H, Haznedaroglu IC, Chao NJ (2001). "Acute graft-vs-host disease: pathobiology and management". Exp. Hematol. 29 (3): 259–77. PMID 11274753.
- ↑ Lee SJ, Vogelsang G, Flowers ME (2003). "Chronic graft-versus-host disease". Biol. Blood Marrow Transplant. 9 (4): 215–33. doi:10.1053/bbmt.2003.50026. PMID 12720215.